Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Bruno Dubois; Howard H. Feldman; Claudia Jacova; Harald Hampel; Jose Luis Molinuevo; Kaj Blennow; Steven T. Dekosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B. Frisoni; Nick C. Fox; Douglas Galasko; Marie-Odile Habert; Gregory A. Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stephane Epelbaum; Leonardo C. de Souza; Bruno Vellas; Pieter J. Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L. Cummings

doi:10.1016/S1474-4422(14)70090-0

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Bruno Dubois^*, Howard H. Feldman, Claudia Jacova, Harald Hampel, Jose Luis Molinuevo, Kaj Blennow, Steven T. Dekosky, Serge Gauthier, Dennis Selkoe, Randall Bateman, Stefano Cappa, Sebastian Crutch, Sebastiaan Engelborghs, Giovanni B. Frisoni, Nick C. Fox, Douglas Galasko, Marie-Odile Habert, Gregory A. Jicha, Agneta Nordberg, Florence PasquierGil Rabinovici, Philippe Robert, Christopher Rowe, Stephen Salloway, Marie Sarazin, Stephane Epelbaum, Leonardo C. de Souza, Bruno Vellas, Pieter J. Visser, Lon Schneider, Yaakov Stern, Philip Scheltens, Jeffrey L. Cummings

^*Corresponding author for this work

MHeNs - Cognitive Neuropsychiatry and Clinical Neuroscience

Research output: Contribution to journal › Article › Academic › peer-review

1975 Citations (Web of Science)

Abstract

In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of Alzheimer's pathology. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fiuorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the predinical states of AD.

Original language	English
Pages (from-to)	614-629
Journal	Lancet Neurology
Volume	13
Issue number	6
DOIs	https://doi.org/10.1016/S1474-4422(14)70090-0
Publication status	Published - Jun 2014

Access to Document

10.1016/S1474-4422(14)70090-0

Cite this

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., Dekosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M-O., Jicha, G. A., Nordberg, A., ... Cummings, J. L. (2014). Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, 13(6), 614-629. https://doi.org/10.1016/S1474-4422(14)70090-0

@article{7393931343fe451abfc45fff6bc7f9e5,

title = "Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria",

abstract = "In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of Alzheimer's pathology. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fiuorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the predinical states of AD.",

author = "Bruno Dubois and Feldman, {Howard H.} and Claudia Jacova and Harald Hampel and Molinuevo, {Jose Luis} and Kaj Blennow and Dekosky, {Steven T.} and Serge Gauthier and Dennis Selkoe and Randall Bateman and Stefano Cappa and Sebastian Crutch and Sebastiaan Engelborghs and Frisoni, {Giovanni B.} and Fox, {Nick C.} and Douglas Galasko and Marie-Odile Habert and Jicha, {Gregory A.} and Agneta Nordberg and Florence Pasquier and Gil Rabinovici and Philippe Robert and Christopher Rowe and Stephen Salloway and Marie Sarazin and Stephane Epelbaum and {de Souza}, {Leonardo C.} and Bruno Vellas and Visser, {Pieter J.} and Lon Schneider and Yaakov Stern and Philip Scheltens and Cummings, {Jeffrey L.}",

year = "2014",

month = jun,

doi = "10.1016/S1474-4422(14)70090-0",

language = "English",

volume = "13",

pages = "614--629",

journal = "Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Science",

number = "6",

}

Dubois, B, Feldman, HH, Jacova, C, Hampel, H, Molinuevo, JL, Blennow, K, Dekosky, ST, Gauthier, S, Selkoe, D, Bateman, R, Cappa, S, Crutch, S, Engelborghs, S, Frisoni, GB, Fox, NC, Galasko, D, Habert, M-O, Jicha, GA, Nordberg, A, Pasquier, F, Rabinovici, G, Robert, P, Rowe, C, Salloway, S, Sarazin, M, Epelbaum, S, de Souza, LC, Vellas, B, Visser, PJ, Schneider, L, Stern, Y, Scheltens, P & Cummings, JL 2014, 'Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria', Lancet Neurology, vol. 13, no. 6, pp. 614-629. https://doi.org/10.1016/S1474-4422(14)70090-0

TY - JOUR

T1 - Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

AU - Dubois, Bruno

AU - Feldman, Howard H.

AU - Jacova, Claudia

AU - Hampel, Harald

AU - Molinuevo, Jose Luis

AU - Blennow, Kaj

AU - Dekosky, Steven T.

AU - Gauthier, Serge

AU - Selkoe, Dennis

AU - Bateman, Randall

AU - Cappa, Stefano

AU - Crutch, Sebastian

AU - Engelborghs, Sebastiaan

AU - Frisoni, Giovanni B.

AU - Fox, Nick C.

AU - Galasko, Douglas

AU - Habert, Marie-Odile

AU - Jicha, Gregory A.

AU - Nordberg, Agneta

AU - Pasquier, Florence

AU - Rabinovici, Gil

AU - Robert, Philippe

AU - Rowe, Christopher

AU - Salloway, Stephen

AU - Sarazin, Marie

AU - Epelbaum, Stephane

AU - de Souza, Leonardo C.

AU - Vellas, Bruno

AU - Visser, Pieter J.

AU - Schneider, Lon

AU - Stern, Yaakov

AU - Scheltens, Philip

AU - Cummings, Jeffrey L.

PY - 2014/6

Y1 - 2014/6

N2 - In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of Alzheimer's pathology. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fiuorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the predinical states of AD.

AB - In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of Alzheimer's pathology. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fiuorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the predinical states of AD.

U2 - 10.1016/S1474-4422(14)70090-0

DO - 10.1016/S1474-4422(14)70090-0

M3 - Article

SN - 1474-4422

VL - 13

SP - 614

EP - 629

JO - Lancet Neurology

JF - Lancet Neurology

IS - 6

ER -